Advertisement

Current Rheumatology Reports

, Volume 5, Issue 2, pp 160–167 | Cite as

Ethnicity and race and systemic sclerosis: How it affects susceptibility, severity, antibody genetics, and clinical manifestations

  • John D. Reveille
Article

Abstract

Most studies have suggested that ethnic factors impact significantly on systemic sclerosis. Extensive epidemiologic studies have been carried out in white individuals, and limited data suggest that blacks are affected twice as frequently; Japanese patients have a lower prevalence than whites. This highest rate that has been described has been in Choctaw Native Americans. Blacks have a lower age at onset, as well as a higher frequency of diffuse skin involvement, pulmonary disease, and an overall worse prognosis than whites. Limited data in Hispanics and Native Americans suggest that they have more severe disease than whites. Whites have the highest frequency of anti-centromere antibodies (associated with limited skin involvement and less pulmonary fibrosis), whereas blacks have a higher frequency of anti-ribonucleoprotein and fibrillarin autoantibodies; the latter is a nucleolar antibody associated with a poorer prognosis. Ethnic differences are also seen for associations with non-major histocompatibility complex genes, such as FBN1 (fibrillin) genes, in Choctaws and Japanese and SPARC (osteonectin) in whites, Hispanics, and Choctaws. Although these facts do not entirely rule out socioeconomic factors associated with ethnicity, nevertheless ethnicity has an important impact on the pathogenesis of systemic sclerosis, perhaps because of genetic factors.

Keywords

Rheumatol Scleroderma Systemic Sclerosis Black Patient Major Histocompatibility Complex Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Underhill PA, Shen P, Lin AA, et al.: Y chromosome sequence variation and the history of human populations. Nat Genet 2000, 26:358–361.CrossRefPubMedGoogle Scholar
  2. 2.
    Cooper RS, Freeman VL: Limitations in the use of race in the study of disease causation. J Natl Med Assoc 1999, 91:379–383.PubMedGoogle Scholar
  3. 3.
    Risch N, Burchard E, Ziv E, Tang H: Categorization of humans in biomedical research: genes, race and disease. Genome Biol 2002, 3:2007.CrossRefGoogle Scholar
  4. 4.
    Medsger TA Jr., Masi AT: The epidemiology of systemic sclerosis (scleroderma) among male US veterans. J Chronic Dis 1978, 31:73–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Michet CJ Jr., McKenna CH, Elveback LR, et al.: Epidemiology of systemic lupus erythematosus and other connective tissue disease in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985, 60:105–113.PubMedGoogle Scholar
  6. 6.
    Maricq HR, Weinrich MC, Keil JE, LeRoy EC: Prevalence of Raynaud phenomenon in the general population: a preliminary study by questionnaire. J Chronic Dis 1986, 39:423–427.CrossRefPubMedGoogle Scholar
  7. 7.
    Steen VD, Oddis CV, Conte CG, et al.: Incidence of systemic sclerosis in Allegheny County, Pennsylvania: a twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum 1997, 40:441–445.CrossRefPubMedGoogle Scholar
  8. 8.
    Mayes MD, Laing TJ, Gillespie BW, et al.: Prevalence, incidence and survival rates of systemic sclerosis in the Detroit Metropolitan Area. Arthritis Rheum 1996, 39:S150.Google Scholar
  9. 9.
    Silman A, Jannini S, Symmons D, Bacon P: An epidemiologic study of scleroderma in the West Midlands. Br J Rheumatol 1988, 27:286–290.CrossRefPubMedGoogle Scholar
  10. 10.
    Eason RJ, Tan PL, Gow PJ: Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust N Z J Med 1981, 11:657–662.PubMedGoogle Scholar
  11. 11.
    Englert H, Small-McMahon J, Davis K, et al.: Systemic sclerosis prevalence and mortality in Sydney 1974–1988. Aust N Z J Med 1999, 29:42–50.PubMedGoogle Scholar
  12. 12.
    Roberts-Thomson PJ, Jones M, Hakendorf P, et al.: Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J 2001, 31:220–229.CrossRefPubMedGoogle Scholar
  13. 13.
    Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V: Systemic sclerosis in Iceland: a nationwide epidemiological study. Ann Rheum Dis 1994, 53:502–505.PubMedGoogle Scholar
  14. 14.
    Arnett FC, Howard RF, Tan F, et al.: Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian haplotype. Arthritis Rheum 1996, 39:1362–1370.CrossRefPubMedGoogle Scholar
  15. 15.
    Tamaki T, Mori S, Takehara K: Epidemiologic study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991, 283:366–371.CrossRefPubMedGoogle Scholar
  16. 16.
    Reveille JD, Fischbach M, McNearney T, et al.: Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001, 30:332–346. An important paper.CrossRefPubMedGoogle Scholar
  17. 17.
    Laing TJ, Gillespie BW, Toth MB, et al.: Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997, 40:734–742.CrossRefPubMedGoogle Scholar
  18. 18.
    Greidinger EL, Flaherty KT, White B, et al.: African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998, 114:801–807.PubMedGoogle Scholar
  19. 19.
    Tager RE, Tikly M: Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in black South Africans. Rheumatology (Oxford) 1999, 38: 397–400.CrossRefGoogle Scholar
  20. 20.
    Krishnamurthy V, Porkodi R, Ramakrishnan S, et al.: Progressive systemic sclerosis in south India. J Assoc Physicians India 1991, 39:254–257.PubMedGoogle Scholar
  21. 21.
    Panicheewa S, Chitrabamrung S, Verasertniyom O, et al.: Diffuse systemic sclerosis and related diseases in Thailand. Clin Rheumatol 1991, 10:124–129.CrossRefPubMedGoogle Scholar
  22. 22.
    McNeilage LJ, Youngchaiyud U, Whittingham S: Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989, 32:54–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Kuwana M, Kaburaki J, Arnett FC, et al.: Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999, 42:465–474.CrossRefPubMedGoogle Scholar
  24. 24.
    Masi AT, D’Angelo WA: Epidemiology of fatal systemic sclerosis (diffuse scleroderma): a 15-year survey in Baltimore. Ann Intern Med 1967, 66:870–883.PubMedGoogle Scholar
  25. 25.
    Walsh SJ, Fenster JR: Geographical clustering of mortality from systemic sclerosis in the Southeastern United States, 1981–1990. J Rheumatol 1997, 24:2348–2352.PubMedGoogle Scholar
  26. 26.
    Nietert PJ, Silverstein MD, Silver RM: Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol 2001, 28:2031–2037.PubMedGoogle Scholar
  27. 27.
    Steen VD, Conte C, Owens GR, Medsger TA Jr.: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283–1289.CrossRefPubMedGoogle Scholar
  28. 28.
    Vlachoyiannopoulos PG, Dagni UG, Pakas I, et al.: Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000, 59:359–367.CrossRefPubMedGoogle Scholar
  29. 29.
    Altman RD, Medsger TA Jr., Bloch DA, Michel BA: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991, 34:403–413.CrossRefPubMedGoogle Scholar
  30. 30.
    Nishioka K, Katayama I, Kondo H, et al.: Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 1996, 23:677–682.PubMedGoogle Scholar
  31. 31.
    Kuwana M, Kaburaki J, Okano Y, et al.: Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994, 37:75–83.CrossRefPubMedGoogle Scholar
  32. 32.
    Reveille JD, Solomon DH, the American College of Rheumatology Ad Hoc Committee on Immunological Testing Guidelines: Evidence-based guidelines for the use of immunological laboratory tests: anti-centromere, Scl-70 and nucleolar antibodies. Arthritis Rheum 2003, In press. A good article.Google Scholar
  33. 33.
    Davis P, Stein M, Ley H, Johnston C: Serological profiles in the connective tissue diseases in Zimbabwean patients. Ann Rheum Dis 1989, 48:73–76.PubMedGoogle Scholar
  34. 34.
    Pudifin DJ, Dinnematin H, Duursma J: Antinuclear antibodies in systemic sclerosis: clinical and ethnic associations. S Afr Med J 1991, 80:438–440.PubMedGoogle Scholar
  35. 35.
    Reveille JD, Durban E, Goldstein R, et al.: Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992, 35:216–218.CrossRefPubMedGoogle Scholar
  36. 36.
    Kuwana M, Okano Y, Kaburaki J, et al.: Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994, 37:902–906.CrossRefPubMedGoogle Scholar
  37. 37.
    Arnett FC, Hamilton RG, Roebber MG, et al.: Increased frequency of Sm and RNP antibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheumatol 1988, 15:1773–1776.PubMedGoogle Scholar
  38. 38.
    Arnett FC, Reveille JD, Goldstein R, et al.: Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996, 39:1151–1160.CrossRefPubMedGoogle Scholar
  39. 39.
    Tormey VJ, Bunn CC, Denton CP, Black CM: Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001, 40:1157–1162.CrossRefGoogle Scholar
  40. 40.
    Tan FK, Arnett FC, Reveille JD, et al.: Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 2000, 43:2464–2471.CrossRefPubMedGoogle Scholar
  41. 41.
    Morel PA, Chang HJ, Wilson JW, et al.: HLA and ethnic associations among systemic sclerosis patients with anticentromere antibodies. Hum Immunol 1995, 42:35–42.CrossRefPubMedGoogle Scholar
  42. 42.
    Vargas-Alarcon G, Granados J, Ibanez de Kasep G, et al.: Association of HLA-DR5 (DR11) with systemic sclerosis (scleroderma) in Mexican patients. Clin Exp Rheumatol 1995, 13:11–16.PubMedGoogle Scholar
  43. 43.
    Briggs DC, Vaughan RW, Welsh KI, et al.: A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis. Arthritis Rheum 1993, 36:943–954.CrossRefPubMedGoogle Scholar
  44. 44.
    Tan FK, Stivers DN, Arnett FC, et al.: HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). Tissue Antigens 1999, 53:74–80.CrossRefPubMedGoogle Scholar
  45. 45.
    Akimoto S, Abe M, Ishikawa O: HLA-DRB1 and DQB1 genes in Japanese patients with systemic sclerosis. J Rheumatol 2000, 27:2940–2942.PubMedGoogle Scholar
  46. 46.
    Kang SH, Park MH, Song EY, et al.: Association of HLA class II genes with systemic sclerosis in Koreans. J Rheumatol 2001, 28:1577–1583.PubMedGoogle Scholar
  47. 47.
    Reveille JD: Molecular genetics of systemic sclerosis. Curr Opin Rheumatol 1995, 7:522–528.CrossRefPubMedGoogle Scholar
  48. 48.
    Kuwana M, Inoko H, Kameda H, et al.: Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. Intern Med 1999, 38: 336–344.PubMedGoogle Scholar
  49. 49.
    Kuwana M, Kaburaki J, Okano Y, et al.: The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest 1993, 92:1296–1301.PubMedCrossRefGoogle Scholar
  50. 50.
    Pandey JP, Takeuchi F: TNF-alpha and TNF-beta gene polymorphisms in systemic sclerosis. Hum Immunol 1999, 60:1128–1130.CrossRefPubMedGoogle Scholar
  51. 51.
    Takeuchi F, Nabeta H, Fussel M, et al.: Association of the TNFa13 microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis 2000, 59:293–296.CrossRefPubMedGoogle Scholar
  52. 52.
    Takeuchi F, Kuwata S, Nakano K, et al.: Association of TAP1 and TAP2 with systemic sclerosis in Japanese. Clin Exp Rheumatol 1996, 14:513–521.PubMedGoogle Scholar
  53. 53.
    Wallis DD, Tan FK, Kielty CM, et al.: Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001, 44:1855–1864.CrossRefPubMedGoogle Scholar
  54. 54.
    Siracusa LD, McGrath R, Ma Q, et al.: A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996, 6:300–313.CrossRefPubMedGoogle Scholar
  55. 55.
    Tan FK, Stivers DN, Foster MW, et al.: Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 1998, 41:1729–1737.CrossRefPubMedGoogle Scholar
  56. 56.
    Tan FK, Wang N, Kuwana M, et al.: Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001, 44:893–901.CrossRefPubMedGoogle Scholar
  57. 57.
    Zhou X, Tan FK, Reveille JD, et al.: SPARC is over-expressed in dermal fibroblasts and shows genetic association with scleroderma (systemic sclerosis). Arthritis Rheum 2002, In press.Google Scholar
  58. 58.
    Mayes MD, Reveille JD: Epidemiology, demographics, and genetics of systemic sclerosis. In Systemic Sclerosis. Edited by Furst DE, Clements PJ. Philadelphia: Lippincott, Williams & Wilkins; 2003: In press.Google Scholar
  59. 59.
    Harvey G, Black C, Maddison P, McHugh N: Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 1997, 24:477–484.PubMedGoogle Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • John D. Reveille
    • 1
  1. 1.Division of Rheumatology and Clinical ImmunogeneticsThe University of Texas Health Sciences Center at HoustonHoustonUSA

Personalised recommendations